InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（12 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
12
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Foley Todd, 董事. Insider active across 3 companies, notably Repare Therapeutics Inc.. Cumulatively, 14 disclosures have been recorded. Breakdown: 0 buy · 12 sells. Total volume traded: €5.4m. Activity tracked since 18 May 2021. The latest transaction was disclosed on 9 July 2021 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Foley Todd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报14 总计
597,391 股Common StockSEC:0001473930-26-000005:0
3,816,760 股Common StockSEC:0001209191-21-062981:0
1,792 股@ US$33.060.9% 占其流量Common SharesSEC:0001209191-21-046493:0
6,080 股@ US$34.063.2% 占其流量Common SharesSEC:0001209191-21-044005:0
2,697 股@ US$33.531.4% 占其流量Common SharesSEC:0001209191-21-043473:0
2,556 股@ US$33.801.3% 占其流量Common SharesSEC:0001209191-21-042802:0
13,575 股@ US$33.787.1% 占其流量Common SharesSEC:0001209191-21-041948:0
881 股@ US$33.090.4% 占其流量Common SharesSEC:0001209191-21-040963:0
3,985 股@ US$32.802.0% 占其流量Common SharesSEC:0001209191-21-039426:0
9,824 股@ US$31.924.8% 占其流量Common SharesSEC:0001209191-21-038751:0
7,377 股@ US$32.673.7% 占其流量Common SharesSEC:0001209191-21-037345:0
2,852 股@ US$32.871.4% 占其流量Common SharesSEC:0001209191-21-036354:0
133,359 股@ US$34.8070.3% 占其流量Common SharesSEC:0001209191-21-035560:0
6,509 股@ US$33.903.3% 占其流量Common SharesSEC:0001209191-21-034628:0
14 条申报中的 14 条
About Foley Todd
Foley Todd is Administrateur and has 14 filings in total. In the 14 sampled filings, all transactions are sales for a total of EUR 5397526, with filing dates from 2021-05-20 to 2026-01-14. The main filings concern Repare Therapeutics Inc., including EUR 3796111.45512496 on 2021-05-24, EUR 384913.5939904517 on 2021-06-21, EUR 258453.7194440663 on 2021-06-07, EUR 197656.7381807104 on 2021-06-02, EUR 180509.7775338806 on 2021-05-20, and EUR 173599.1831423178 on 2021-06-30. He is also a director of Repare Therapeutics Inc., AKTIS ONCOLOGY, INC. and Entrada Therapeutics, Inc.
